Houston Methodist. Leading Medicine.
Houston Methodist. Leading Medicine

Methodist J.C. Walter Jr. Transplant Center - Houston, TX

Current/On-going Research

Dr. Howard Monsour

Total: 7 projects

  1. Protocol HGS1008-C1060: A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or PEG-IFNα2a) in Combination with Ribavirin in Interferon Alfa Naïve Subjects with Chronic Hepatitis C Genotype 1 (ACHIEVE-1)- active

  2. Long-Term Follow-up of Subjects in a Phase 2 or 3 Clinical Trial in Which SCH 503034 was Adminsitered for the Treatment of Chronic Hepatitis C –active

  3. A Phase 3b, Randomized, Double-Blind, Double Dummy Study Evaluating the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy versus Emtriciabine plus Tenofovir DF Fixed-Dose Combination Therapy in Subjects with Chronic Hepatitis B who are resistant to Lamivudine.

  4. A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50mg Versus Esomeprazole 40mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD).

  5. A Phase 3 Safety and Efficacy Study of Boceprevir in Subjects with Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment with Peginterferon/Ribavirin.

  6. A Phase 3, Safety and Efficacy Study of Boceprevir in Previously Untreated Subjects with Chronic Hepatitis C Genotype 1.

  7. A Randomized, Double-Blind, Placebo-controlled, Phase III trial of 2 regimens of Telaprevir (with and without delayed start) combined with pegylated interferon alfa-2a (Pegasys) and ribavirin (Copegus) in subjects with Chronic genotype 1 Hepatitis C infection who failed prior pegylated interferon plus Ribavirin treatment.